Biotechnology · Boston, Massachusetts, United States
$24.51
+3.86% (+$0.91)2026-08-24
Smart-Money SignalNeutral · 53/100— Insiders are net sellers over 90 days (-$1.7M, 9 sales vs 9 buys)
Revenue$0
Net Income-$55.3M
EPS$-0.68
Market Cap$4.1B
Price Performance
Historical data including institutional events
Company Profile
M
Malte Peters
CEO & Executive Director
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need.
The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma.
It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase (STK) 11 loss-of-function mutations to treat lung cancer.
The company was founded in 2017 and is headquartered in Boston, Massachusetts.
